Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 3,701 | 3,040 | 32 | 348 | 19,145 |
| Gross Profit | 3,701 | 3,040 | 32 | 348 | 19,145 |
| Operating Expenses | 68,565 | 61,460 | 66,012 | 55,491 | 54,780 |
| Operating Income | -64,864 | -58,420 | -65,980 | -55,143 | -35,635 |
| Other Income | 729 | 9,979 | -8,943 | -16,862 | 18,271 |
| Pre-tax Income | -64,135 | -48,441 | -74,923 | -72,005 | -17,364 |
| Net Income Continuous | -64,135 | -48,441 | -74,923 | -72,005 | -17,364 |
| Net Income | $-64,135 | $-48,441 | $-74,923 | $-72,005 | $-17,364 |
| EPS Basic Total Ops | -0.52 | -0.40 | -0.62 | -0.61 | -0.15 |
| EPS Basic Continuous Ops | -0.52 | -0.40 | -0.63 | -0.61 | -0.15 |
| EPS Diluted Total Ops | -0.52 | -0.40 | -0.62 | -0.61 | -0.15 |
| EPS Diluted Continuous Ops | -0.52 | -0.40 | -0.63 | -0.61 | -0.15 |
| EPS Diluted Before Non-Recurring Items | -0.52 | -0.40 | -0.63 | -0.41 | -0.15 |
| EBITDA(a) | $-64,805 | $-58,358 | $-65,921 | $-55,079 | $-35,590 |